Srihari Gopal
Johnson & Johnson (United States)(US)
Publications by Year
Research Areas
Schizophrenia research and treatment, Pharmaceutical studies and practices, Mental Health and Psychiatry, Bipolar Disorder and Treatment, Botulinum Toxin and Related Neurological Disorders
Most-Cited Works
- → Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study(2009)264 cited
- → Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia(2015)218 cited
- → A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia(2010)215 cited
- → A Comparison of Ten Polygenic Score Methods for Psychiatric Disorders Applied Across Multiple Cohorts(2021)198 cited
- → Estimation of Genetic Correlation via Linkage Disequilibrium Score Regression and Genomic Restricted Maximum Likelihood(2018)198 cited
- → Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview(2021)174 cited
- → A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia(2010)169 cited
- → Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study(2010)169 cited
- → A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia(2010)161 cited
- → Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study(2016)160 cited